NCT04756648View on ClinicalTrials.gov

Phase I Clinical Trial of CT0180 Cells in the Treatment of Hepatocellular Carcinoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

March 10, 2021

Primary Completion Date

March 31, 2023

Study Completion Date

June 1, 2026

Conditions
Advanced Hepatocellular Carcinoma
Interventions
DRUG

CT0180 Cells

Five dose levels were tentatively determined.

Trial Locations (1)

310006

First affiliated hospital, Zhejiang University, Hangzhou

Sponsors
All Listed Sponsors
collaborator

CARsgen Therapeutics Co., Ltd.

INDUSTRY

lead

Zhejiang University

OTHER

NCT04756648 - Phase I Clinical Trial of CT0180 Cells in the Treatment of Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter